Cyclo Therapeutics, Inc. (CYTH)
After hours:
| Previous Close | 1.3000 |
| Open | 1.3000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.2800 - 1.3700 |
| 52 Week Range | 0.8900 - 2.5700 |
| Volume | |
| Avg. Volume | 91,436 |
| Market Cap | 36.628M |
| Beta (5Y Monthly) | -0.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9200 |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.20 |
- Business Wire
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
GAINESVILLE, Fla., May 30, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the last patient has been enrolled in the Company’s pivotal Phase 3 study ("TransportNPC™") evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type
- Business Wire
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GAINESVILLE, Fla., May 16, 2024--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter 2024 and provided a business update.
Simply Wall St.Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
